StockData
OKYO Pharma Ltd logo

OKYO Pharma Ltd (OKYO) income statement

OKYONasdaqBiological Products, (No Diagnostic Substances)
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 20, 2026Score 1/30
$1.11−0.06 (-5.13%)

Close on Nov 17, 2026Market cap $58.25MP/E –Yield –

OKYO Pharma Ltd income statement

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2026
–

Financial strength

Current ratio
2.43
Debt to equity
–
Debt to assets
–
Cash to current liabilities
168.9%

Valuation

P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–

See a number that looks wrong?